Eisai Europe Limited

Pharmaceuticals, Biotechnology and Life Sciences

Targets set1.5°CNet-Zero: Targets set

SBTI ID

40012036

Informations générales

Localisation

United Kingdom

Europe

Secteur d'activité

Pharmaceuticals, Biotechnology and Life Sciences

Type d'organisation

Corporate

Dernière mise à jour

11/07/2024

Objectifs à court terme (Near-Term)
Engagement de réduction des émissions à horizon FY2032

Statut

Targets set

Classification

1.5°C

Année cible

FY2032

Progression vers l'objectif0%
2015 (année de référence)FY2032
Objectifs à long terme (Long-Term)
Engagement de réduction des émissions à horizon FY2045

Statut

Targets set

Classification

1.5°C

Année cible

FY2045

Progression vers l'objectif0%
2015 (année de référence)FY2045
Description complète des objectifs

Overall Net-Zero Target: Eisai Europe Limited commits to reach net-zero greenhouse gas emissions across the value chain by FY2045. Near-Term Targets: Eisai Europe Limited commits to reduce absolute scope 1 and 2 GHG emissions 62% by FY2032 from a FY2022 base year. Eisai Europe Limited also commits to reduce absolute scope 3 GHG emissions 41% within the same timeframe. Eisai Europe Limited further commits to increase active annual sourcing of renewable electricity from 98% in FY2022 to 100% by FY2030. Long-Term Targets: Eisai Europe Limited commits to reduce absolute scope 1 and 2 GHG emissions by 90% by FY2045 from a FY2022 base year. Eisai Europe Limited also commits to reduce absolute scope 3 GHG emissions by 90% within the same timeframe.

Net-Zero

Statut

Targets set

Année cible

FY2045

Progression0%
Business Ambition 1.5°C

Statut

BA1.5 member

Date d'engagement

30/09/2021

Classification détaillée

The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C

Identifiants

LEI

21380063M56OQ1O3W564

Source : Science Based Targets initiative | Données publiques